Hypermethylation of<i>DAPK1</i>is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma

Lasse S. Kristensen, Fazila Asmar, Konstantinos Dimopoulos, Mette Nygaard, Derya Aslan, Jakob Werner Hansen, Kirsten Grønbæk

Oncotarget · 2014 · 35 citations · 28 references

DOIFull text

Open access

Concepts

Abstract

// Lasse Sommer Kristensen 1 , Fazila Asmar 1 , Konstantinos Dimopoulos 1 , Mette Kathrine Nygaard 2 , Derya Aslan 1 , Jakob Werner Hansen 1 , Elisabeth Ralfkiaer 3 , Kirsten Gr&oslash;nb&aelig;k 1 1 Department of Haematology, Rigshospitalet, Blegdamsvej 9, 2100-DK, Copenhagen, Denmark 2 Department of Haematology, Aalborg University Hospital, M&oslash;lleparkvej 4, 9000-DK, Aalborg, Denmark 3 Department of Pathology, Rigshospitalet, Copenhagen, Denmark Correspondence to: Lasse Sommer Kristensen, e-mail: lasse.sommer.kristensen@regionh.dk Keywords: Diffuse Large B-Cell Lymphoma, Rituximab, prognostic markers, allele-specific DNA methylation, DAPK, DAPK1, mutations, TP53 Received: August 20, 2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accepted: August 21, 2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Published: November 12, 2014 ABSTRACT Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin&rsquo;s lymphoma. Improvements in overall survival have been observed with the introduction of rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), however, prognostic markers are still needed. Methylation of the death associated protein kinase ( DAPK or DAPK1 ) gene and TP53 mutations are likely to have prognostic value in DLBCL. We have assessed TP53 mutations and allelic DAPK1 methylation patterns in a cohort of 119 DLBCL patients uniformly treated with R-CHOP-like regimens. We found that DAPK1 promoter methylation was associated with shorter overall survival ( p =0.017) and disease-specific survival ( p =0.023). In multivariate analyses DAPK1 methylation remained as an independent prognostic factor predicting disease-specific survival ( p =0.038). When only considering individuals heterozygous for the rs13300553 SNP monoallelic methylation of the A-allele was associated with shorter overall- and disease-specific survival ( p &lt;0.001). Patients carrying both DAPK1 methylation and a TP53 mutation had an inferior survival compared to patients carrying only one of these molecular alterations, however, this was borderline statistically significant. Allele-specific DAPK1 methylation patterns were also studied in a cohort of 67 multiple myeloma patients, and all of the methylated multiple myeloma samples heterozygous for the rs13300553 SNP were methylated on both alleles.

References

28